FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204196228> ?p ?o ?g. }

• W3204196228 abstract "With the revolutionary progress of immune checkpoint inhibitors (ICIs) achieved in non-small cell lung cancers (NSCLC), identifying patients benefiting from ICIs becomes critical and urgent. The associations of genomic alterations in protein tyrosine phosphatase receptor-type (PTPRs) and ICIs responses are unknown.Whole-exome sequencing (WES) of 73 advanced NSCLC tumors sampled before anti-PD-(L)1 therapy was carried out with corresponding clinical data collected as a discovery cohort to find the associations of PTPR mutations and ICI responses. Three validation cohorts consolidated by 7 public cohorts of 1920 NSCLC patients with WES or target sequencing data of tumor tissue-derived DNA or circulating tumor DNA (ctDNA) and relevant clinical data were applied as validation cohorts. The lung adenocarcinoma (LUAD) cohort (n=586) in The Cancer Genome Atlas (TCGA) database was used for analyzing the potential anti-tumor immunologic mechanisms.With the highest mutation frequency among all PTPRs, PTPRD mutations in non-squamous NSCLC (ns-NSCLC) were linked to longer progression-free survivals (PFS, 324 vs 63 days, hazard ratio (HR)=0.36, p= 0.0152) and higher objective response rate (ORR, p=0.0099). In validation cohort 1 (n=377), ns-NSCLC patients with tissue PTPRD mutations had favorable PFS (9.10 vs 4.33 months, HR=0.62, p=0.0184) and ORR (p=0.013). In validation cohort 2 (n=406), ns-NSCLC patients with tissue PTPRD mutations had favorable overall survivals (OS, over 40 vs 11.94 months, HR=0.57, p=0.011). In validation cohort 3 (n=1137), ns-NSCLC patients with ctDNA PTPRD mutations had longer PFS (6.97 vs 2.73 months, HR=0.63, p=0.028) and higher ORR (p=0.047). Moreover, it was deleterious mutations in phosphatase domains (phosphatase-mut), rather than other mutations (other-mut), that were responsible of PTPRD's prediction efficiency. In addition, in validation cohort 3, ctDNA phosphatase-mut also functioned as a predictive biomarker helping identify patients benefiting more from ICIs than chemotherapy (interaction P for PFS=0.0506, for OS=0.04). Univariate and multivariate regression analysis revealed that phosphatase-mut was independent on PD-L1 expression and tumor mutation burden (TMB) to predict. In silico analysis based on TCGA LUAD cohort discovered enhanced anti-tumor immunity in phosphatase-mut patients.Tissue or ctDNA PTPRD phosphatase domain deleterious mutations might function as a both prognostic and predictive biomarker predicting clinical outcomes of ICIs in ns-NSCLC patients, independent on TMB or PD-L1 expression." @default.
• W3204196228 created "2021-10-11" @default.
• W3204196228 creator A5004343457 @default.
• W3204196228 creator A5006822602 @default.
• W3204196228 creator A5013952915 @default.
• W3204196228 creator A5032952041 @default.
• W3204196228 creator A5037773587 @default.
• W3204196228 creator A5046131158 @default.
• W3204196228 creator A5059643185 @default.
• W3204196228 creator A5063835503 @default.
• W3204196228 creator A5065264579 @default.
• W3204196228 creator A5066716873 @default.
• W3204196228 creator A5069193020 @default.
• W3204196228 creator A5075877965 @default.
• W3204196228 creator A5083051605 @default.
• W3204196228 date "2021-10-07" @default.
• W3204196228 modified "2023-10-14" @default.
• W3204196228 title "Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC" @default.
• W3204196228 cites W1982488143 @default.
• W3204196228 cites W2011398963 @default.
• W3204196228 cites W2024405748 @default.
• W3204196228 cites W2040604770 @default.
• W3204196228 cites W2049553585 @default.
• W3204196228 cites W2082279608 @default.
• W3204196228 cites W2085517091 @default.
• W3204196228 cites W2114843025 @default.
• W3204196228 cites W2124427232 @default.
• W3204196228 cites W2134582937 @default.
• W3204196228 cites W2149441684 @default.
• W3204196228 cites W2288894747 @default.
• W3204196228 cites W2302489581 @default.
• W3204196228 cites W2557730509 @default.
• W3204196228 cites W2560367415 @default.
• W3204196228 cites W2561459036 @default.
• W3204196228 cites W2570114214 @default.
• W3204196228 cites W2572174216 @default.
• W3204196228 cites W2783897381 @default.
• W3204196228 cites W2788431960 @default.
• W3204196228 cites W2794195501 @default.
• W3204196228 cites W2796046027 @default.
• W3204196228 cites W2796207838 @default.
• W3204196228 cites W2797675588 @default.
• W3204196228 cites W2797855256 @default.
• W3204196228 cites W2803397860 @default.
• W3204196228 cites W2804812017 @default.
• W3204196228 cites W2804957255 @default.
• W3204196228 cites W2886963239 @default.
• W3204196228 cites W2888546921 @default.
• W3204196228 cites W2890888376 @default.
• W3204196228 cites W2909679049 @default.
• W3204196228 cites W2916508569 @default.
• W3204196228 cites W2925446385 @default.
• W3204196228 cites W2942610007 @default.
• W3204196228 cites W2947219786 @default.
• W3204196228 cites W2950192777 @default.
• W3204196228 cites W2965386138 @default.
• W3204196228 cites W2966455969 @default.
• W3204196228 cites W2966972050 @default.
• W3204196228 cites W2981193577 @default.
• W3204196228 cites W2981470547 @default.
• W3204196228 cites W2985170860 @default.
• W3204196228 cites W2992258096 @default.
• W3204196228 cites W2996038327 @default.
• W3204196228 cites W3008059924 @default.
• W3204196228 cites W3014961679 @default.
• W3204196228 cites W3037432438 @default.
• W3204196228 cites W3082530149 @default.
• W3204196228 cites W3112041723 @default.
• W3204196228 doi "https://doi.org/10.1186/s12916-021-02075-5" @default.
• W3204196228 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8496052" @default.
• W3204196228 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34615542" @default.
• W3204196228 hasPublicationYear "2021" @default.
• W3204196228 type Work @default.
• W3204196228 sameAs 3204196228 @default.
• W3204196228 citedByCount "11" @default.
• W3204196228 countsByYear W32041962282022 @default.
• W3204196228 countsByYear W32041962282023 @default.
• W3204196228 crossrefType "journal-article" @default.
• W3204196228 hasAuthorship W3204196228A5004343457 @default.
• W3204196228 hasAuthorship W3204196228A5006822602 @default.
• W3204196228 hasAuthorship W3204196228A5013952915 @default.
• W3204196228 hasAuthorship W3204196228A5032952041 @default.
• W3204196228 hasAuthorship W3204196228A5037773587 @default.
• W3204196228 hasAuthorship W3204196228A5046131158 @default.
• W3204196228 hasAuthorship W3204196228A5059643185 @default.
• W3204196228 hasAuthorship W3204196228A5063835503 @default.
• W3204196228 hasAuthorship W3204196228A5065264579 @default.
• W3204196228 hasAuthorship W3204196228A5066716873 @default.
• W3204196228 hasAuthorship W3204196228A5069193020 @default.
• W3204196228 hasAuthorship W3204196228A5075877965 @default.
• W3204196228 hasAuthorship W3204196228A5083051605 @default.
• W3204196228 hasBestOaLocation W32041962281 @default.
• W3204196228 hasConcept C104317684 @default.
• W3204196228 hasConcept C121608353 @default.
• W3204196228 hasConcept C126322002 @default.
• W3204196228 hasConcept C143998085 @default.
• W3204196228 hasConcept C16671776 @default.
• W3204196228 hasConcept C207103383 @default.
• W3204196228 hasConcept C2776256026 @default.
• W3204196228 hasConcept C2779177807 @default.

• next